Heptares to Present at Upcoming Biotech Industry Conferences
WELWYN GARDEN CITY, England and BOSTON, June 6, 2013 /PRNewswire/ –
Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be
presenting at the following biotech industry events over the coming weeks.
EPIC European Partnering and Investment Conference [http://www.epicbiotech.com ]
(London, UK, 6 June)
Dr Barry Kenny, Heptares’ Chief Business Officer, will present an overview of the
Company at 4:00pm (BST).
Boston Biotech CEO Conference
[http://bbbiotechconference.com/conference-details.php?id=11 ] (Boston, MA, USA, 11-12
Mr Dan Grau, Heptares’ President, will participate in a panel discussion entitled
Building Technology Value: A Checklist of Essentials, at 10:30am (EDT) on 12 June.
For a full list of events at which Heptares will be present, please visit
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically
challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked
to a wide range of human diseases. Leveraging our advanced structure-based drug design
technology platform, we have built an exciting discovery and development pipeline of novel
drug candidates, which have the potential to transform the treatment of serious diseases,
including Alzheimer’s disease, Parkinson’s disease, schizophrenia, migraine and diabetes.
Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and
MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis
Venture Fund and Takeda Ventures. To learn more about Heptares, please visit
SOURCE Heptares Therapeutics